Therapeutics


Working Group Leads

Jonathan Abraham Jonathan Abraham, M.D., Ph.D. 
Assistant Professor of Microbiology, HMS
Associate Member, Broad Institute of Harvard and MIT
Associate Physician, Infectious Diseases, BWH
Mark Namchuk Mark Namchuk, Ph.D.
Executive Director of Therapeutics Translation, HMS

 

Therapeutics Working Group

Fueled by the ongoing need for safe and effective therapies against COVID-19 as well as other emerging viral pathogens, the Therapeutics Working Group formed to coalesce efforts to study and identify therapeutic strategies beyond vaccines. Another, equally important, aspect of the work’s group is to use the latest data and analytics to identify ineffective treatments. To date, the only approved antiviral drug to treat COVID-19 is remdesivir. However, the group continues to explore potential candidates, including both novel compounds and repurposed drugs. The questions pursued by the researchers go beyond drug development and include defining the optimal therapeutic window for initiating various types of treatment depending on the stage of infection. Another important aspect of the group’s work is conducting fundamental research aimed at developing pan-viral therapeutics, including small-molecule treatments.

The research conducted by the Group aims to address both the immediate challenges posed by SARS-CoV-2 and the long-range challenges of infection response and pandemic preparedness bound to arise from emerging viral pathogens.

To join the Therapeutics Working Group, please fill out this form.